Tsubota Laboratory Incorporated (JP:4890)
:4890
Want to see JP:4890 full AI Analyst Report?
Top Page
Tsubota Laboratory Incorporated
(4890)
Select Model
Select Model
Rating:43Neutral
Price Target:
¥211.00
▼(-37.94% Downside)
Action:Reiterated
Date:05/16/26
The score is primarily weighed down by sharp 2026 fundamental deterioration (major revenue drop, deep losses) and persistent negative cash flow, with additional pressure from a bearish technical setup (below key moving averages, negative MACD). A low-debt balance sheet provides some resilience but is not enough to offset the current operating and cash-burn risks.
Positive Factors
Conservative balance sheet
Low leverage and substantial equity provide a durable financial cushion that reduces bankruptcy risk and preserves flexibility. This conservative capital structure supports the ability to fund operations or restructure without immediate distressed financing, giving management time to address operational issues.
Negative Factors
Severe revenue collapse
An 85% year-over-year revenue drop is a structural red flag, implying loss of a major product, contract, or market access. Such a collapse destroys scale economics, weakens pricing leverage, and makes returning to prior profit levels dependent on material commercial or product recoveries.
Read all positive and negative factors
Positive Factors
Negative Factors
Conservative balance sheet
Low leverage and substantial equity provide a durable financial cushion that reduces bankruptcy risk and preserves flexibility. This conservative capital structure supports the ability to fund operations or restructure without immediate distressed financing, giving management time to address operational issues.
Read all positive factors
Tsubota Laboratory Incorporated (4890) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥5.65B
Dividend YieldN/A
Average Volume (3M)31.02K
Price to Earnings (P/E)―
Beta (1Y)0.10
Revenue Growth-85.26%
EPS Growth-468.26%
CountryJP
Employees7
SectorHealthcare
Sector Strength45
IndustryMedical - Pharmaceuticals
Share Statistics
EPS (TTM)6.97
Shares Outstanding25,794,300
10 Day Avg. Volume26,720
30 Day Avg. Volume31,016
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)8.77
Price to Sales (P/S)37.86
P/FCF Ratio-12.91
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Tsubota Laboratory Incorporated Business Overview & Revenue Model
Company Description
Operating from Tokyo, Japan since its establishment in 2012, Tsubota Laboratory Incorporated is dedicated to the research and development of pharmaceutical products and medical devices, specifically targeting the treatment of myopia, dry eyes, and...
How the Company Makes Money
null...
Tsubota Laboratory Incorporated Financial Statement Overview
Summary
Income Statement
27
Negative
Balance Sheet
73
Positive
Cash Flow
18
Very Negative
| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.36B | 200.02M | 1.36B | 673.53M | 954.69M | 640.92M |
| Gross Profit | 1.15B | 131.57M | 1.15B | -9.48M | 686.83M | 528.76M |
| EBITDA | 219.47M | -765.24M | 262.46M | -609.24M | 206.22M | 173.87M |
| Net Income | 178.16M | -761.82M | 205.77M | -641.32M | 90.18M | 153.32M |
Balance Sheet | ||||||
| Total Assets | 2.02B | 1.32B | 2.50B | 2.30B | 2.67B | 1.62B |
| Cash, Cash Equivalents and Short-Term Investments | 1.47B | 969.85M | 1.54B | 1.88B | 2.16B | 1.17B |
| Total Debt | 85.26M | 69.21M | 90.38M | 116.90M | 139.34M | 223.82M |
| Total Liabilities | 627.88M | 454.92M | 915.85M | 927.93M | 722.59M | 873.44M |
| Stockholders Equity | 1.39B | 863.86M | 1.59B | 1.37B | 1.95B | 744.35M |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | -586.61M | -331.75M | -313.35M | -15.27M | 582.69M |
| Operating Cash Flow | 0.00 | -577.83M | -317.75M | -301.35M | 28.49M | 654.91M |
| Investing Cash Flow | 0.00 | -8.41M | -14.55M | -12.00M | -54.03M | -72.23M |
| Financing Cash Flow | 0.00 | 17.23M | -12.25M | 35.74M | 1.01B | -18.53M |
Tsubota Laboratory Incorporated Technical Analysis
Negative
340.00
Price Trends
278.88
Negative
297.21
Negative
323.46
Negative
Market Momentum
-18.58
Positive
27.77
Positive
21.32
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4890, the sentiment is Negative. The current price of 340 is above the 20-day moving average (MA) of 241.60, above the 50-day MA of 278.88, and above the 200-day MA of 323.46, indicating a bearish trend. The MACD of -18.58 indicates Positive momentum. The RSI at 27.77 is Positive, neither overbought nor oversold. The STOCH value of 21.32 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:4890.
Tsubota Laboratory Incorporated Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
68 Neutral | ¥449.10B | 14.31 | 11.37% | 3.04% | 5.08% | 2.07% | |
67 Neutral | ¥364.39B | 18.82 | ― | 0.41% | 14.59% | 7.84% | |
66 Neutral | ¥551.29B | 11.77 | 15.71% | 0.96% | 15.07% | 72.98% | |
62 Neutral | ¥935.35B | 22.61 | ― | 1.72% | ― | ― | |
60 Neutral | ¥483.65B | 15.34 | ― | 0.93% | 6.74% | 6.60% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
43 Neutral | ¥5.65B | -7.41 | ― | ― | -85.26% | -468.26% |
* Healthcare Sector Average
JP:4890
Tsubota Laboratory Incorporated
219.00
-186.00
-45.93%
JP:9989
Sundrug Co
3,841.00
-420.03
-9.86%
JP:7649
Sugi Holdings Co
2,925.00
-203.07
-6.49%
JP:3391
TSURUHA Holdings
2,079.00
-138.64
-6.25%
JP:3349
COSMOS Pharmaceutical Corporation
6,076.00
-2,937.26
-32.59%
JP:3549
KUSURI NO AOKI HOLDINGS CO.,LTD.
3,811.00
330.13
9.48%
Tsubota Laboratory Incorporated Corporate Events
Tsubota Lab Emphasizes ‘VISIONary INNOVATION’ in Vision and Brain Health
May 20, 2026
Tsubota Lab Co., an RD-based venture from Keio University’s School of Medicine, concentrates on medical and healthcare innovations targeting visual function disorders such as myopia, dry eye, and presbyopia, as well as brain diseases. Its bu...
Tsubota Laboratory Swings to Loss but Projects Sharp Rebound in 2027
May 15, 2026
Tsubota Laboratory reported a sharp downturn in non-consolidated results for the fiscal year ended March 31, 2026, with revenue plunging 85.3% to ¥200 million and swinging from a prior-year profit to a net loss of ¥761 million. The compa...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.